These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 31027925)

  • 1. Evaluation of future cervical cancer risk in Japan, based on birth year.
    Yagi A; Ueda Y; Ikeda S; Sekine M; Nakayama T; Miyagi E; Enomoto T
    Vaccine; 2019 May; 37(22):2889-2891. PubMed ID: 31027925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A nationwide birth year-by-year analysis of effectiveness of HPV vaccine in Japan.
    Yagi A; Ueda Y; Nakagawa S; Masuda T; Miyatake T; Ikeda S; Abe H; Hirai K; Sekine M; Miyagi E; Enomoto T; Nakayama T; Kimura T
    Cancer Sci; 2021 Sep; 112(9):3691-3698. PubMed ID: 34252250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of catch-up and routine program of the 9-valent vaccine on cervical cancer risk reduction in Japan.
    Yagi A; Nakagawa S; Ueda Y; Oka E; Ikeda S; Kakuda M; Kobayashi E; Ito Y; Katayama K; Hirai K; Nakayama T; Kimura T
    Cancer Sci; 2024 Mar; 115(3):916-925. PubMed ID: 38158850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
    Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
    BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lower Incidence of Cervical Intraepithelial Neoplasia among Young Women with Human Papillomavirus Vaccination in Miyagi, Japan.
    Ozawa N; Ito K; Tase T; Shibuya D; Metoki H; Yaegashi N
    Tohoku J Exp Med; 2017 Dec; 243(4):329-334. PubMed ID: 29269635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corrected human papillomavirus vaccination rates for each birth fiscal year in Japan.
    Nakagawa S; Ueda Y; Yagi A; Ikeda S; Hiramatsu K; Kimura T
    Cancer Sci; 2020 Jun; 111(6):2156-2162. PubMed ID: 32248632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A questionnaire survey on the prevention of HPV infection among females and males who came of age in Japan under various scenarios of HPV vaccine recommendation.
    Ishimoto T; Yagi A; Nakajima K; Okamoto N; Yukimitsu E; Kawasaki M; Kawae Y; Hayasaka S; Ueda Y; Kimura T
    Hum Vaccin Immunother; 2023 Aug; 19(2):2229222. PubMed ID: 37462048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Human papillomavirus (HPV) vaccines--a new method for the prevention of cervical cancer].
    Friedek DA; Ekiel AM; Martirosian G
    Wiad Lek; 2007; 60(1-2):34-8. PubMed ID: 17607966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can Catch-Up Vaccinations Fill the Void Left by Suspension of the Governmental Recommendation of HPV Vaccine in Japan?
    Yagi A; Ueda Y; Nakagawa S; Ikeda S; Kakuda M; Hiramatsu K; Miyoshi A; Kobayashi E; Kimura T; Mizushima T; Suzuki Y; Sekine M; Hirai K; Nakayama T; Miyagi E; Enomoto T; Kimura T
    Vaccines (Basel); 2022 Sep; 10(9):. PubMed ID: 36146533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the epidemiological impact on cervical cancer of switching from 4-valent to 9-valent HPV vaccine within a gender-neutral vaccination programme in Switzerland.
    Kind AB; Pavelyev A; Kothari S; El Mouaddin N; Schmidt A; Morais E; Guggisberg P; Lienert F
    BMC Public Health; 2020 May; 20(1):671. PubMed ID: 32398057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Educational intervention for women in Japan coming of age for cervical cancer screening who grew up during the suspended HPV-vaccination-program.
    Miyoshi A; Ueda Y; Yagi A; Kimura T; Kobayashi E; Hiramatsu K; Nakagawa S; Kimura T
    Hum Vaccin Immunother; 2021 Nov; 17(11):4418-4422. PubMed ID: 35016492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends and future projections of cervical cancer-related outcomes in Japan: What happens if the HPV vaccine program is not implemented?
    Sakakibara A; Nakayama T; Uchida H; Odagiri Y; Ito Y; Katayama T; Ueda Y; Higuchi T; Terakawa K; Matsui K; Miyazaki K; Konishi I
    Int J Cancer; 2023 May; 152(9):1863-1874. PubMed ID: 36468173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study.
    Palmer T; Wallace L; Pollock KG; Cuschieri K; Robertson C; Kavanagh K; Cruickshank M
    BMJ; 2019 Apr; 365():l1161. PubMed ID: 30944092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human Papillomavirus Vaccination by Birth Fiscal Year in Japan.
    Yagi A; Ueda Y; Oka E; Nakagawa S; Kimura T
    JAMA Netw Open; 2024 Jul; 7(7):e2422513. PubMed ID: 39012629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of human papillomavirus vaccination on the clinical meaning of cervical screening results.
    Castle PE; Xie X; Xue X; Poitras NE; Lorey TS; Kinney WK; Wentzensen N; Strickler HD; Burger EA; Schiffman M
    Prev Med; 2019 Jan; 118():44-50. PubMed ID: 30316878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human papillomavirus vaccine to prevent cervical intraepithelial neoplasia in Japan: A nationwide case-control study.
    Ikeda S; Ueda Y; Hara M; Yagi A; Kitamura T; Kitamura Y; Konishi H; Kakizoe T; Sekine M; Enomoto T; Sobue T
    Cancer Sci; 2021 Feb; 112(2):839-846. PubMed ID: 33040433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Roles of extended human papillomavirus genotyping and multiple infections in early detection of cervical precancer and cancer and HPV vaccination.
    Song F; Yan P; Huang X; Wang C; Du H; Qu X; Wu R
    BMC Cancer; 2022 Jan; 22(1):42. PubMed ID: 34991494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HPV Vaccine Issues in Japan: A review of our attempts to promote the HPV vaccine and to provide effective evaluation of the problem through social-medical and behavioral-economic perspectives.
    Yagi A; Ueda Y; Kimura T
    Vaccine; 2024 Sep; 42(22):125859. PubMed ID: 38616440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Declining rates of cervical intraepithelial neoplasia in British Columbia, Canada: An ecological analysis on the effects of the school-based human papillomavirus vaccination program.
    Donken R; van Niekerk D; Hamm J; Spinelli JJ; Smith L; Sadarangani M; Albert A; Money D; Dobson S; Miller D; Lee M; Mitchell-Foster S; Krajden M; Naus M; Ogilvie G
    Int J Cancer; 2021 Jul; 149(1):191-199. PubMed ID: 33586169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.